D-mannose as a new therapy for fucokinase deficiency-related congenital disorder of glycosylation (FCSK-CDG)
- 9 May 2024
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 142 (2) , 108488
Abstract
No abstract availableKeywords
Funding Information
- Washington University in St. Louis
- National Center for Advancing Translational Sciences
- National Institute of Neurological Disorders and Stroke (1U54NS115198-01)
This publication has 26 references indexed in Scilit:
- Fractionated plasma N‐glycan profiling of novel cohort of ATP6AP1‐CDG subjects identifies phenotypic associationJournal of Inherited Metabolic Disease, 2023
- N‐glycoproteomics reveals distinct glycosylation alterations in NGLY1‐deficient patient‐derived dermal fibroblastsJournal of Inherited Metabolic Disease, 2022
- A case with congenital disorder of glycosylation with defective fucosylation 2 and new mutation in FUK geneBrain and Development, 2022
- Congenital disorders of glycosylation with defective fucosylationJournal of Inherited Metabolic Disease, 2021
- International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1‐CDG): Diagnosis, follow‐up, and managementJournal of Inherited Metabolic Disease, 2020
- Consensus guideline for the diagnosis and management of mannose phosphate isomerase‐congenital disorder of glycosylationJournal of Inherited Metabolic Disease, 2020
- Pathogenic Variants in Fucokinase Cause a Congenital Disorder of GlycosylationThe American Journal of Human Genetics, 2018
- Unmasking Fucosylation: from Cell Adhesion to Immune System Regulation and DiseasesCell Chemical Biology, 2018
- Distinct fucosylation of M cells and epithelial cells by Fut1 and Fut2, respectively, in response to intestinal environmental stressBiochemical and Biophysical Research Communications, 2011
- Characterisation of the Sek‐1 receptor tyrosine kinaseFEBS Letters, 1995